Literature DB >> 26516549

Cancer pain physiology.

Sarah Falk1, Kirsty Bannister2, Anthony H Dickenson2.   

Abstract

Mechanisms of inflammatory and neuropathic pains have been elucidated and translated to patient care by the use of animal models of these pain states. Cancer pain has lagged behind since early animal models of cancer-induced bone pain were based on the systemic injection of carcinoma cells. This precluded systematic investigation of specific neuronal and pharmacological alterations that occur in cancer-induced bone pain. In 1999, Schwei et al. described a murine model of cancer-induced bone pain that paralleled the clinical condition in terms of pain development and bone destruction, confined to the mouse femur. This model prompted related approaches, and we can now state that cancer pain may include elements of inflammatory and neuropathic pains but also unique changes in sensory processing. Cancer-induced bone pain results in progressive bone destruction, elevated osteoclast activity and distinctive nocifensive behaviours (indicating the triad of ongoing, spontaneous and movement-induced hyperalgesia). In addition, cancer cells induce an inflammatory infiltrate and release growth factors, cytokines, interleukins, chemokines, prostanoids and endothelins, resulting in a reduction of pH to below 5 and direct deformation of primary afferents within bone. These peripheral changes, in turn, drive hypersensitivity of spinal cord sensory neurons, many of which project to the parts of the brain involved in the emotional response to pain. Within the spinal cord, a unique neuronal function reorganization within segments of the dorsal horn of the spinal cord receiving nociceptive input from the bone are discussed. Changes in certain neurotransmitters implicated in brain modulation of spinal function are also altered with implications for the affective components of cancer pain. Treatments are described in terms of mechanistic insights and in the case of opioids, which modulate pain transmission at spinal and supraspinal sites, their use can be compromised by opioid-induced hyperalgesia. We discuss evidence for how this comes about and how it may be treated.

Entities:  

Keywords:  Cancer pain; cancer-induced bone pain; opioid-induced hyperalgesia; peripheral and central pain mechanisms; spinal modulation

Year:  2014        PMID: 26516549      PMCID: PMC4616725          DOI: 10.1177/2049463714545136

Source DB:  PubMed          Journal:  Br J Pain        ISSN: 2049-4637


  73 in total

Review 1.  Molecular mechanisms of nociception.

Authors:  D Julius; A I Basbaum
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

2.  Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways.

Authors:  Rie Suzuki; Sara Morcuende; Mark Webber; Stephen P Hunt; Anthony H Dickenson
Journal:  Nat Neurosci       Date:  2002-12       Impact factor: 24.884

3.  Tapentadol in cancer pain management: a prospective open-label study.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Patrizia Ferrera; Federica Aielli; Claudio Adile; Corrado Ficorella; Antonello Giarratano; Alessandra Casuccio
Journal:  Curr Med Res Opin       Date:  2012-10-26       Impact factor: 2.580

4.  Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain.

Authors:  Juan Miguel Jimenez-Andrade; Joseph R Ghilardi; Gabriela Castañeda-Corral; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2011-09-09       Impact factor: 6.961

5.  A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy.

Authors:  Elizabeth A Matthews; Anthony H Dickenson
Journal:  Anesthesiology       Date:  2002-03       Impact factor: 7.892

6.  Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur.

Authors:  D B Mach; S D Rogers; M C Sabino; N M Luger; M J Schwei; J D Pomonis; C P Keyser; D R Clohisy; D J Adams; P O'Leary; P W Mantyh
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 8.  Bisphosphonates: mechanism of action and role in clinical practice.

Authors:  Matthew T Drake; Bart L Clarke; Suneep Khosla
Journal:  Mayo Clin Proc       Date:  2008-09       Impact factor: 7.616

9.  Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology.

Authors:  Kirsty Bannister; Shafaq Sikandar; Claudia S Bauer; Annette C Dolphin; Frank Porreca; Anthony H Dickenson
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

Review 10.  Clinical development of anti-RANKL therapy.

Authors:  Edward M Schwarz; Christopher T Ritchlin
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  16 in total

1.  Cancer pain for the 21st century: stepping off the ladder, stepping up to new challenges.

Authors:  Sam H Ahmedzai
Journal:  Br J Pain       Date:  2014-11

Review 2.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 3.  Interventional Therapies for Pain in Cancer Patients: a Narrative Review.

Authors:  David Hao; Shawn Sidharthan; Juan Cotte; Mary Decker; Mariam Salisu-Orhurhu; Dare Olatoye; Jay Karri; Jonathan M Hagedorn; Peju Adekoya; Charles Odonkor; Amitabh Gulati; Vwaire Orhurhu
Journal:  Curr Pain Headache Rep       Date:  2021-05-07

4.  A Survey of Knowledge and Barriers of Healthcare Professionals toward Opioid Analgesics in Cancer Pain Management.

Authors:  Nehad M Ayoub; Malak Jibreel; Khawla Nuseir; Ghaith M Al-Taani
Journal:  Int J Clin Pract       Date:  2022-04-12       Impact factor: 3.149

5.  Differences and Similarities in Spontaneous Activity Between Animal Models of Cancer-Induced Pain and Neuropathic Pain.

Authors:  Yong Fang Zhu; Peter Kan; Gurmit Singh
Journal:  J Pain Res       Date:  2022-10-12       Impact factor: 2.832

Review 6.  Mechanisms Underlying Bone and Joint Pain.

Authors:  Joshua Havelin; Tamara King
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

7.  Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial.

Authors:  Neil A Hagen; Lyne Cantin; John Constant; Tina Haller; Gilbert Blaise; May Ong-Lam; Patrick du Souich; Walter Korz; Bernard Lapointe
Journal:  Pain Res Manag       Date:  2017-05-07       Impact factor: 3.037

8.  Repetitive Transcranial Magnetic Stimulation as a Promising Potential Therapeutic Modality for the Management of Cancer-related Pain: An Issue that Merits Further Research.

Authors:  Amir Emami Zeydi; Ravanbakhsh Esmaeili; Farshad Hasanzadeh Kiabi; Hassan Sharifi
Journal:  Indian J Palliat Care       Date:  2017 Jan-Mar

9.  Methadone in Swedish specialized palliative care-Is it the magic bullet in complex cancer-related pain?

Authors:  Per Fürst; Staffan Lundström; Peter Strang
Journal:  PLoS One       Date:  2020-04-10       Impact factor: 3.240

Review 10.  Inferior Hypogastric Block for the Treatment of Chronic Pelvic Pain.

Authors:  Ivan Urits; Ruben Schwartz; Harish Bangalore Siddaiah; Sathyadev Kikkeri; David Chernobylsky; Karina Charipova; Jai Won Jung; Farnad Imani; Mohsen Khorramian; Giustino Varrassi; Elyse M Cornett; Alan David Kaye; Omar Viswanath
Journal:  Anesth Pain Med       Date:  2021-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.